Patent · US Active

Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders

US9393198B2 · kind B2 · utility

0Cited by

18References

15Claims

0Family size

Assignee

Signpath Pharma Inc. · US

Inventors

Lawrence Helson · Quakertown, US
Simon Chiu · London, CA

Key dates

Filing date	Mar 21, 2011
Grant date	Jul 19, 2016
Priority date	—
Expiry date	Mar 21, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Liposomal formulations and polymer conjugates of curcumin, curcumin analogs and derivatives thereof for parenteral administration are disclosed herein. The formulations are effective in the treatment of progressive supranuclear palsy, Alzheimer's disease (AD), Parkinson's disease (PD), Tauopathies or stress disorders including Post Traumatic Stress Disorder (PTSD). Curcumin crosses the blood brain barrier, localizes in the hippocampus and striata, prevents stress-induced neuronal cell damage, and stimulates neurogenesis and remediation of damaged neural circuits.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.